Adial Pharmaceuticals, Inc. announced that it has appointed Professor Tomáš Zima, MD, DSc, Dr.h.c. and Professor Sebastian Mueller, MD, PhD as its next two Scientific Advisory Board (SAB) members. Doctors Zima and Mueller bring broad and diversified experience in areas such as addiction, genetics and the diagnosis and treatment of alcohol related diseases. They join Dr. Giovanni Addolorato, who was selected as Adial’s first SAB member and Chairperson in November 2018. The SAB is charged with helping to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019. Professor Tomáš Zima, MD, DSc. Dr.h.c. is the Rector (Chancellor) of Charles University of Prague and the President of the Czech Rectors’ Conference. He was the Dean of the First Faculty of Medicine at Charles University between 2005-2012 and served as a professor of medical chemistry and biochemistry since 2001 and head of the Institute of Medical Biochemistry and Laboratory Medicine at Charles University since 1999. Sebastian Mueller is Professor of Medicine and the current Vice Head of the Department of Internal Medicine at Salem Medical Center and the Co-Director of the Center for Alcohol Research at the University of Heidelberg. Since 2017, he has served as president of the European Society of Biomedical Research on Alcoholism (ESBRA). Prof. Mueller studied medicine in Leipzig, Denver and Strasbourg and obtained a PhD in biophysics, was a gastroenterology resident and consultant in Heidelberg, postdoctoral Humboldt fellow at USC in Los Angeles, and lecturer at the BIDMC/Harvard Medical School.